MARKET

MLNT

MLNT

Melinta
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.680
+0.280
+20.00%
After Hours: 1.690 +0.01 +0.60% 16:09 11/15 EST
OPEN
1.370
PREV CLOSE
1.400
HIGH
1.870
LOW
1.355
VOLUME
1.69M
TURNOVER
--
52 WEEK HIGH
14.25
52 WEEK LOW
1.030
MARKET CAP
23.10M
P/E (TTM)
-0.0672
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of MLNT and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 6 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

MLNT News

  • Microcaps mostly among midday movers
  • Seeking Alpha - Article.2d ago
  • Melinta Therapeutics, Inc. Just Reported Earnings, And Analysts Cut Their Target Price
  • Simply Wall St..2d ago
  • The Daily Biotech Pulse: Amarin Braces For Vascepa Adcom Verdict, Biotechs On A Fundraising Spree, Zosano Makes Progress With Migraine Drug Filing
  • Benzinga.3d ago
  • Melinta down 44% on liquidity concerns
  • seekingalpha.4d ago

More

Industry

Biotechnology & Medical Research
+1.25%
Pharmaceuticals & Medical Research
+1.34%

Hot Stocks

Name
Price
%Change

About MLNT

Melinta Therapeutics, Inc. develops and commercializes novel antibiotics designed to provide therapeutic solutions. The Company’s lead product is Baxdela, an antibiotic approved by the United States food and drug administration (FDA) for use in the treatment of acute bacterial skin and skin structure infections (ABSSSI). The Company also has an extensive pipeline of preclinical and clinical stage products This pipeline includes many important classes of antibiotics, each targeted at a different segment of the anti-infective market.
More

Webull offers Melinta Therapeutics Inc (MLNT) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.